Skip to main content

Century Therapeutics, Inc.

corporate_fare Company Profile

Century Therapeutics, Inc.

IPSC·NASDAQ·Life Sciences·CIK 0001850119

We are a biotechnology company that develops cell therapy products for autoimmune diseases, including type 1 diabetes (T1D), and cancer. Our beta islet, T cell, and NK cell programs use allogeneic cells, meaning they are derived from healthy donors for use in any patient. We focus on induced pluripotent stem cells (iPSCs), which can self-renew indefinitely and differentiate into any cell type, allowing for genetic editing, consistent reproducibility, and scalable manufacturing. Our allogeneic cell therapy platform includes: * iPSCs and expertise in differentiating them into fully functional mature cells. * CRISPR-mediated precision gene editing to incorporate multiple transgenes and disrupt target genes to optimize cell product performance. * Our proprietary Allo-Evasion™ technology, designed to prevent the host immune system from rejecting our cell products, potentially allowing for persistence and re-dosing. * Manufacturing capabilities aimed at achieving scale advantages and reducing the cost of goods sold (COGs), while minimizing product development and supply risk. We use our expertise in cellular reprogramming, differentiation, genetic engineering, and manufacturing to develop therapies. We can generate various cell types from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ ab T cells (ab iT cells), and iPSC-natural killer cells (iNK cells).

Century Therapeutics, Inc. (NASDAQ:IPSC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 16 items for IPSC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-12, rated 7/10. Across its 16 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for IPSC spans 8-K, 10-Q, DEF 14A, PRE 14A.

Recent high-impact activity:

  • Century Therapeutics Reports Q2 2026 Results: $197.2M Cash Runway into 2029, CNTY-813 IND on Track for Q4
  • Century Therapeutics Q2 2026: Cash Runway Extended to 2029, Pipeline Advances Amid Cost Cuts
  • Century Therapeutics Reports Q2 Cash Runway Into 2029, FDA Alignment on CNTY-813 IND Path
  • Chief Scientific Officer Transitions to Part-Time Role with Reduced Salary
  • Century Therapeutics Shareholders Approve 50% Increase in Authorized Common Stock

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$109.16M
Net Income
-$9.58M
Diluted EPS
-$0.14
Op. Cash Flow
-$103.88M
Free Cash Flow
-$104.72M
Operating Income
-$17.27M
Cash & Equivalents
$61.85M
Debt / Equity
0.00×
Net Margin
-8.8%
Shares Outstanding
87.52M sh
Source: 10-K · filed 2026-03-12 · accession 0001104659-26-026759

Short Interest & Short Volume

30.96 days to cover

FINRA reported short interest of 32,026,662 shares in IPSC as of the October 30, 2026 settlement, a 9.9% increase from the prior period — about 31.0 days to cover at its recent average daily volume. On November 19, 2026, 58.7% of IPSC volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)32,026,662 shares as of October 30, 2026
Change vs prior period▲ 9.9%
Days to cover30.96 at avg daily volume of 1,034,597
Daily short volume (FINRA facilities)58.7% of 309,355 shares on November 19, 2026
5-day average short volume56.6%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with I →
$1.33 +0.76% today
52-week range · as of 2026-08-12 $0.435 – $3.04
Market cap
$239.71M
Volume
815.6K (0.9× avg)
3-mo avg 922.1K
Live data · 2026-11-20 12:59 UTC · Pre-market

show_chartPrice Chart

Loading chart...

feed IPSC - Latest Insights

IPSC
Aug 12, 2026, 8:12 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.07
Real-time Price: $1.33 info
Change: -$0.740 (-36%) info
Market Cap: $239.708M info
IPSC
Aug 12, 2026, 8:01 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.98
Real-time Price: $1.33 info
Change: -$0.650 (-33%) info
Market Cap: $239.708M info
IPSC
Aug 12, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.07
Real-time Price: $1.33 info
Change: -$0.740 (-36%) info
Market Cap: $239.708M info
IPSC
Jun 16, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.18
Real-time Price: $1.33 info
Change: -$0.850 (-39%) info
Market Cap: $239.708M info
IPSC
Jun 12, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.25
Real-time Price: $1.33 info
Change: -$0.920 (-41%) info
Market Cap: $239.708M info
IPSC
Jun 08, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $2.15
Real-time Price: $1.33 info
Change: -$0.820 (-38%) info
Market Cap: $239.708M info
IPSC
May 13, 2026, 8:01 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $2.30
Real-time Price: $1.33 info
Change: -$0.970 (-42%) info
Market Cap: $239.708M info
IPSC
Apr 27, 2026, 4:49 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $2.25
Real-time Price: $1.33 info
Change: -$0.920 (-41%) info
Market Cap: $239.708M info
IPSC
Apr 16, 2026, 4:07 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $2.45
Real-time Price: $1.33 info
Change: -$1.12 (-46%) info
Market Cap: $239.708M info
IPSC
Mar 26, 2026, 4:42 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.00
Real-time Price: $1.33 info
Change: -$0.6711 (-34%) info
Market Cap: $239.708M info
IPSC
Mar 26, 2026, 4:40 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $2.00
Real-time Price: $1.33 info
Change: -$0.6711 (-34%) info
Market Cap: $239.708M info
IPSC
Mar 12, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $2.77
Real-time Price: $1.33 info
Change: -$1.44 (-52%) info
Market Cap: $239.708M info
IPSC
Mar 12, 2026, 8:04 AM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $2.77
Real-time Price: $1.33 info
Change: -$1.44 (-52%) info
Market Cap: $239.708M info
IPSC
Feb 05, 2026, 4:06 PM EST
Filing Type: S-3
Importance Score:
9
Price at Filing: $1.67
Real-time Price: $1.33 info
Change: -$0.340 (-20%) info
Market Cap: $239.708M info
IPSC
Jan 23, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.42
Real-time Price: $1.33 info
Change: -$1.09 (-45%) info
Market Cap: $239.708M info
IPSC
Jan 08, 2026, 8:05 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.40
Real-time Price: $1.33 info
Change: -$0.070 (-5%) info
Market Cap: $239.708M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets